Related Experiment Video

Updated: Apr 24, 2026

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

790

Lipid mediators in diabetic nephropathy

Swayam Prakash Srivastava1, Sen Shi1, Daisuke Koya2

  • 1Department of Diabetology & Endocrinology, Kanazawa Medical University, Uchinada, Ishikawa 920-0293, Japan.

Fibrogenesis & Tissue Repair
|September 11, 2014
PubMed

Insights

Lipid lowering drugs improve cardiovascular health in chronic kidney disease patients but show limited kidney benefits. Targeting lipid mediators like diacylglycerol and ceramide may offer new therapeutic strategies for diabetic nephropathy.

Area of Science:

  • Nephrology
  • Endocrinology
  • Cardiovascular Medicine

Background:

  • Diabetic nephropathy (DN) is a significant complication of diabetes, leading to kidney damage.
  • Lipid lowering drugs improve cardiovascular outcomes in chronic kidney disease (CKD) patients but have shown limited efficacy in improving kidney outcomes in DN.
  • Lipid mediators play a crucial role in the pathogenesis of DN.

Purpose of the Study:

  • To analyze the involvement of specific lipid mediators in the development of diabetic nephropathy.
  • To explore the potential of targeting lipid metabolism for therapeutic interventions in DN.
  • To investigate the effects of lipid lowering drugs on pathways implicated in DN progression.

Main Methods:

  • Review of existing literature on lipid mediators, diabetic nephropathy, and lipid-lowering therapies.
  • Analysis of the role of diacylglycerol (DAG) and ceramide in hyperglycemia-induced pathways.
  • Examination of the impact of lipid-lowering drugs on protein kinase C (PKC) activation and ceramide synthesis.

Main Results:

  • Hyperglycemia promotes diacylglycerol (DAG) overproduction, activating protein kinase C (PKC) and downstream signaling pathways (VEGF, TGFβ1, PAI-1, NADPH oxidases, NFҟB), which accelerate DN.
  • Excessive ceramide formation is implicated in the pathobiology of DN.
  • Lipid lowering drugs may offer therapeutic benefits by downregulating PKC activation, reducing ceramide synthesis, and upregulating anti-fibrotic microRNAs.

Conclusions:

  • Lipid mediators are key players in the development and progression of diabetic nephropathy.
  • Targeting lipid metabolism, specifically PKC activation and ceramide biosynthesis, presents a promising therapeutic avenue for DN.
  • Further research into the effects of lipid lowering drugs on these pathways is warranted to optimize treatment strategies for DN.

Keywords:
Antidyslipidaemic drugs and microRNAs (miRs)Diabetic nephropathy (DN)Diacylglycerol (DAG)GlyceroshingolpidsProtein kinase Cs (PKCs)

More Related Videos

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

746
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

1.1K

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration...
24
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
45
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
35
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
1.1K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
1.1K